D. Altman and J. Deeks, Meta-analysis, Simpson's paradox, and the number needed to treat, BMC Medical Research Methodology, vol.319, issue.1, 2002.
DOI : 10.1136/bmj.319.7204.259

P. Andersen, P. Perme, and M. , Pseudo-observations in survival analysis, Statistical Methods in Medical Research, vol.19, issue.1, pp.71-99, 2010.
DOI : 10.1177/0962280209105020

P. Andersen, M. Hansen, and J. Klein, Regression Analysis of Restricted Mean Survival Time Based on Pseudo-Observations, Lifetime Data Analysis, vol.93, issue.4, pp.335-350, 2004.
DOI : 10.1007/s10985-004-4771-0

A. Anell and A. Norinder, Health outcome measures used in cost-effectiveness studies: a review of original articles published between 1986 and 1996, Health Policy, vol.51, issue.2, pp.87-99, 2000.
DOI : 10.1016/S0168-8510(00)00058-0

B. Baujat, H. Audry, and J. Bourhis, Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients, International Journal of Radiation Oncology*Biology*Physics, vol.64, issue.1, pp.47-56, 2006.
DOI : 10.1016/j.ijrobp.2005.06.037

P. Blanchard, A. Lee, and S. Marguet, Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. The Lancet Oncology, pp.645-655, 2015.

M. Bobbio, B. Demichelis, and G. Giustetto, Completeness of reporting trial results: effect on physicians' willingness to prescribe, The Lancet, vol.343, issue.8907, pp.1209-1211, 1994.
DOI : 10.1016/S0140-6736(94)92407-4

J. Bowden, J. Tierney, M. Simmonds, A. Copas, and J. Higgins, Individual patient data meta-analysis of time-to-event outcomes: one-stage versus two-stage approaches for estimating the hazard ratio under a random effects model, Research Synthesis Methods, vol.27, issue.2, pp.150-162, 2011.
DOI : 10.1002/jrsm.45

A. Braud, C. Lévy-piedbois, and P. Piedbois, Direct Treatment Costs for Patients with Lung Cancer from First Recurrence to Death in France, PharmacoEconomics, vol.80, issue.9, pp.671-680, 2003.
DOI : 10.2165/00019053-200321090-00005

J. Brown, M. Hollander, and R. Korwar, Nonparametric tests of independence for censored data with application to heart transplant studies. Reliability and Biometry, Statistical Analysis of Lifelength, pp.327-54, 1974.

C. Cates, Simpson's paradox and calculation of number needed to treat from metaanalysis, BMC Medical Research Methodology, vol.2, issue.1, 2002.

P. Chen and A. Tsiatis, Causal Inference on the Difference of the Restricted Mean Lifetime Between Two Groups, Biometrics, vol.93, issue.4, pp.1030-1038, 2001.
DOI : 10.1111/j.0006-341X.2001.01030.x

M. Connock, C. Hyde, and D. Moore, Cautions Regarding the Fitting and Interpretation of Survival Curves, PharmacoEconomics, vol.359, issue.6, pp.827-837, 2011.
DOI : 10.2165/11585940-000000000-00000

J. Cortés, J. González, M. Campbell, and E. Cobo, A hazard ratio was estimated by a ratio of median survival times, but with considerable uncertainty, Journal of Clinical Epidemiology, vol.67, issue.10, pp.1172-1179, 2014.
DOI : 10.1016/j.jclinepi.2014.05.017

D. Cox, Regression Models and Life-Tables, Journal of the Royal Statistical Society, Series B, vol.34, pp.187-220, 1972.
DOI : 10.1007/978-1-4612-4380-9_37

J. Deeks, Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes, Statistics in Medicine, vol.21, issue.11, pp.1575-1600, 2002.
DOI : 10.1002/sim.1188

R. Dersimonian and N. Laird, Meta-analysis in clinical trials, Controlled Clinical Trials, vol.7, issue.3, pp.177-188, 1986.
DOI : 10.1016/0197-2456(86)90046-2

I. Durand-zaleski, B. Roche, and M. Buyse, Economic Implications of Hepatic Arterial Infusion Chemotherapy in Treatment of Nonresectable Colorectal Liver Metastases, JNCI Journal of the National Cancer Institute, vol.89, issue.11, pp.790-795, 1997.
DOI : 10.1093/jnci/89.11.790

K. Dwan, C. Gamble, P. Williamson, and J. Kirkham, Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias ??? An Updated Review, PLoS ONE, vol.31, issue.7, 2013.
DOI : 10.1371/journal.pone.0066844.s003

R. Fisher, Statistical Methods for Resarch Workers, pp.99-101, 1932.

L. Forrow, W. Taylor, and R. Arnold, Absolutely relative: How research results are summarized can affect treatment decisions, The American Journal of Medicine, vol.92, issue.2, pp.121-124, 1992.
DOI : 10.1016/0002-9343(92)90100-P

D. Fried, D. Morris, and C. Poole, Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.22, issue.23, pp.4837-4845, 2004.
DOI : 10.1200/JCO.2004.01.178

P. Glasziou, R. Simes, and R. Gelber, Quality adjusted survival analysis, Statistics in Medicine, vol.76, issue.11, pp.1259-1276, 1990.
DOI : 10.1002/sim.4780091106

D. V. Glidden and E. Vittinghoff, Modelling clustered survival data from multicentre clinical trials, Statistics in Medicine, vol.23, issue.3, pp.369-388, 2004.
DOI : 10.1002/sim.1599

R. Goeree, J. Villeneuve, J. Goeree, J. Penrod, L. Orsini et al., Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes, Journal of Medical Economics, vol.19, issue.6, pp.630-644, 2016.
DOI : 10.3111/13696998.2016.1151432

Q. Gong and L. Fang, Asymptotic properties of mean survival estimate based on the Kaplan-Meier curve with an extrapolated tail, Pharmaceutical Statistics, vol.59, issue.3, pp.135-140, 2012.
DOI : 10.1002/pst.514

P. Grambsch and T. Therneau, Proportional hazards tests and diagnostics based on weighted residuals, Biometrika, vol.81, issue.3, 1994.
DOI : 10.1093/biomet/81.3.515

A. Gray, P. Clarke, J. Wolstenholme, and S. Wordsworth, Applied methods of cost-effectiveness analysis in health care, p.313, 2011.

P. Guyot, N. Welton, M. Ouwens, and A. Ades, Survival Time Outcomes in Randomized, Controlled Trials and Meta-Analyses: The Parallel Universes of Efficacy and Cost-Effectiveness, Value in Health, vol.14, issue.5, pp.640-646, 2011.
DOI : 10.1016/j.jval.2011.01.008

P. Guyot, A. Ades, M. Ouwens, and N. Welton, Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves, BMC Medical Research Methodology, vol.14, issue.3, p.9, 2012.
DOI : 10.1080/1478336032000046643

P. Guyot, A. Ades, M. Beasley, B. Lueza, J. Pignon et al., Extrapolation of Survival Curves from Cancer Trials Using External Information, Medical Decision Making, vol.8, 2016.
DOI : 10.1016/j.radonc.2009.04.014

J. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions, 2011.
DOI : 10.1002/9780470712184

J. Higgins, S. Thompson, J. Deeks, and D. Altman, Measuring inconsistency in meta-analyses, BMJ, vol.327, issue.7414, pp.557-60, 2003.
DOI : 10.1136/bmj.327.7414.557

D. Hosmer, S. Lemeshow, and S. May, The Delta Method Applied Survival Analysis: Regression Modeling of Time-to-Event Data, pp.355-358, 2008.

D. Hosmer, S. Lemeshow, and S. May, Applied Survival Analysis: Regression Modeling of Time to Event Data, 2008.
DOI : 10.1002/9780470258019

J. Irwin, The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice, Journal of Hygiene, vol.47, issue.02, p.188, 1949.
DOI : 10.1017/S0022172400019197

C. Jackson, Survival Models in Health Economic Evaluations: Balancing Fit and Parsimony to Improve Prediction, The International Journal of Biostatistics, vol.6, issue.1, 2010.
DOI : 10.2202/1557-4679.1269

C. Jackson, J. Stevens, S. Ren, N. Latimer, L. Bojke et al., Extrapolating Survival from Randomized Trials Using External Data, Medical Decision Making, vol.9, issue.2, 2016.
DOI : 10.1137/120889563

J. Jansen, Network meta-analysis of survival data with fractional polynomials, BMC Medical Research Methodology, vol.24, issue.28, p.61, 2011.
DOI : 10.2165/00019053-200624010-00001

E. Kaplan and P. Meier, Nonparametric Estimation from Incomplete Observations, Journal of the American Statistical Association, vol.37, issue.282, pp.457-481, 1958.
DOI : 10.1214/aoms/1177731566

T. Karrison, Restricted Mean Life with Adjustment for Covariates, Journal of the American Statistical Association, vol.6, issue.400, pp.1169-1176, 1987.
DOI : 10.1002/9780470316436

T. Karrison, Use of Irwin's restricted mean as an index for comparing survival in different treatment groups???Interpretation and power considerations, Controlled Clinical Trials, vol.18, issue.2, pp.151-167, 1997.
DOI : 10.1016/S0197-2456(96)00089-X

J. Klein and M. Moeschberger, Survival Analysis: techniques for censored and truncated data, 2003.
DOI : 10.1007/978-1-4757-2728-9

K. Lamb, E. Williamson, M. Coory, and J. Carlin, Bias and precision of measures of survival gain from right-censored data, Pharmaceutical Statistics, vol.31, issue.suppl; abstr 40, pp.409-426, 2015.
DOI : 10.1002/pst.1700

N. Latimer, Survival Analysis for Economic Evaluations Alongside Clinical Trials--Extrapolation with Patient-Level Data: Inconsistencies, Limitations, and a Practical Guide, Medical Decision Making, vol.33, issue.6, pp.743-54, 2013.
DOI : 10.1177/0272989X12472398

C. Legrand, V. Ducrocq, P. Janssen, R. Sylvester, and L. Duchateau, A Bayesian approach to jointly estimate centre and treatment by centre heterogeneity in a proportional hazards model, Statistics in Medicine, vol.24, issue.24, pp.3789-3804, 2005.
DOI : 10.1002/sim.2475

B. Lueza, A. Mauguen, J. Pignon, O. Rivero-arias, and J. Bonastre, Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study, PLOS ONE, vol.14, issue.3, 2016.
DOI : 10.1371/journal.pone.0150032.s006
URL : https://hal.archives-ouvertes.fr/inserm-01441469

B. Lueza, F. Rotolo, J. Bonastre, J. Pignon, and S. Michiels, Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis, BMC Medical Research Methodology, vol.15, issue.1, p.37, 2016.
DOI : 10.1371/journal.pone.0150032
URL : https://hal.archives-ouvertes.fr/inserm-01441487

N. Mantel, Evaluation of survival data and two new rank order statistics arising in its consideration, Cancer Chemotherapy Reports, vol.50, pp.163-70, 1966.

P. Martin, Le Coût de la radiothérapie, Bulletin du Cancer, vol.90, pp.969-975, 2003.

A. Mauguen, L. Péchoux, C. Saunders, and M. , Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis, Journal of Clinical Oncology, vol.30, issue.22, pp.2788-97, 2012.
DOI : 10.1200/JCO.2012.41.6677

J. Van-meerbeeck, D. Fennell, D. Ruysscher, and D. , Small-cell lung cancer. The Lancet, pp.1741-1755, 2011.

S. Michiels, B. Baujat, C. Mahé, D. Sargent, and J. Pignon, Random effects survival models gave a better understanding of heterogeneity in individual patient data meta-analyses, Journal of Clinical Epidemiology, vol.58, issue.3, pp.238-283, 2005.
DOI : 10.1016/j.jclinepi.2004.08.013

S. Michiels, P. Piedbois, L. Stewart, and J. Pignon, Meta-analysis when only the median survival times are known: A comparison with individual patient data results, International Journal of Technology Assessment in Health Care, vol.84, issue.01, pp.119-125, 2005.
DOI : 10.1016/S0140-6736(98)06341-7
URL : https://hal.archives-ouvertes.fr/hal-00339603

R. Minacori, J. Bonastre, B. Lueza, S. Marguet, and P. Levy, How to Model Survival In Cost-Effectiveness Analysis? Differences Between Markov and Partitioned Survival Analysis Models, Value in Health, vol.18, issue.7, p.704, 2015.
DOI : 10.1016/j.jval.2015.09.2639

D. Moher, S. Hopewell, and K. Schulz, CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials, BMJ, pp.340-869, 2010.

M. Munda and C. Legrand, Adjusting for centre heterogeneity in multicentre clinical trials with a time-to-event outcome, Pharmaceutical Statistics, vol.3, issue.2, pp.145-152, 2014.
DOI : 10.1002/pst.1612

S. Murray and A. Tsiatis, Sequential Methods for Comparing Years of Life Saved in the Two-Sample Censored Data Problem, Biometrics, vol.82, issue.4, pp.1085-1092, 1999.
DOI : 10.1111/j.0006-341X.1999.01085.x

C. Naylor, E. Chen, and B. Strauss, Measured Enthusiasm: Does the Method of Reporting Trial Results Alter Perceptions of Therapeutic Effectiveness?, Annals of Internal Medicine, vol.117, issue.11, pp.916-937, 1992.
DOI : 10.7326/0003-4819-117-11-916

N. Neymark, I. Adriaenssen, and T. Gorlia, Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer, European Journal of Cancer, vol.37, issue.14, pp.1768-1774, 2001.
DOI : 10.1016/S0959-8049(01)00197-6

N. Neymark, I. Adriaenssen, and T. Gorlia, Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer, Health Economics, vol.19, issue.3, pp.233-248, 2002.
DOI : 10.1002/hec.662

M. Ouwens, Z. Philips, and J. Jansen, Network meta-analysis of parametric survival curves, Research Synthesis Methods, vol.64, issue.4, pp.258-271, 2010.
DOI : 10.1002/jrsm.25

A. Oza, A. Cook, and J. Pfisterer, Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial, The Lancet Oncology, vol.16, issue.8, pp.928-936, 2015.
DOI : 10.1016/S1470-2045(15)00086-8

M. Parmar, V. Torri, and L. Stewart, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Statistics in Medicine, vol.17, issue.24, p.2834, 1998.
DOI : 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8

J. Pignon and C. Hill, Meta-analyses of randomised clinical trials in oncology. The Lancet Oncology, pp.475-482, 2001.

J. Pignon, R. Arriagada, and D. Ihde, A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer, New England Journal of Medicine, vol.327, issue.23, pp.1618-1624, 1992.
DOI : 10.1056/NEJM199212033272302

M. Pijls-johannesma, D. Ruysscher, D. Vansteenkiste, J. Kester, A. Rutten et al., Timing of chest radiotherapy in patients with limited stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials, Cancer Treatment Reviews, vol.33, issue.5, pp.461-473, 2007.
DOI : 10.1016/j.ctrv.2007.03.002

B. Ramaekers, M. Joore, and B. Lueza, Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non???Small-Cell Lung Cancer Patients, Journal of Thoracic Oncology, vol.8, issue.10, pp.1295-1307, 2013.
DOI : 10.1097/JTO.0b013e31829f6c55

R. Riley, P. Lambert, and G. Abo-zaid, Meta-analysis of individual participant data: rationale, conduct, and reporting, BMJ, vol.340, issue.feb05 1, pp.221-221, 2010.
DOI : 10.1136/bmj.c221

U. Rochau, B. Jahn, and V. Qerimi, Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example, Critical Reviews in Oncology/Hematology, vol.94, issue.2, pp.164-178, 2015.
DOI : 10.1016/j.critrevonc.2014.12.017

V. Rondeau, S. Michiels, B. Liquet, and J. Pignon, Investigating trial and treatment heterogeneity in an individual patient data meta-analysis of survival data by means of the penalized maximum likelihood approach, Statistics in Medicine, vol.58, issue.11, pp.1894-1910, 2008.
DOI : 10.1002/sim.3161
URL : https://hal.archives-ouvertes.fr/inserm-00289664

F. Rotolo and S. Michiels, Testing the treatment effect on competing causes of death in oncology clinical trials, BMC Medical Research Methodology, vol.32, issue.18, p.14, 2014.
DOI : 10.1002/sim.5755

P. Royston and M. Parmar, Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects, Statistics in Medicine, vol.1, issue.15, pp.2175-97, 2002.
DOI : 10.1002/sim.1203

P. Royston and M. Parmar, The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt, Statistics in Medicine, vol.19, issue.19, pp.2409-2421, 2011.
DOI : 10.1002/sim.4274

P. Royston and M. Parmar, Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome, BMC Medical Research Methodology, vol.100, issue.S, p.152, 2013.
DOI : 10.1093/jnci/djm265

P. Royston and M. Parmar, Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated, BMC Medical Research Methodology, vol.64, issue.1, p.16, 2016.
DOI : 10.1186/s12874-016-0110-x

G. Rücker and M. Schumacher, Simpson's paradox visualized: The example of the Rosiglitazone meta-analysis, BMC Medical Research Methodology, vol.58, issue.2, p.34, 2008.
DOI : 10.1002/sim.2971

D. De-ruysscher, B. Lueza, L. Péchoux, and C. , Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis, Annals of Oncology, vol.27, issue.10, p.10, 2016.
DOI : 10.1093/annonc/mdw263
URL : https://hal.archives-ouvertes.fr/inserm-01441456

D. Schaubel and G. Wei, Double Inverse-Weighted Estimation of Cumulative Treatment Effects Under Nonproportional Hazards and Dependent Censoring, Biometrics, vol.93, issue.1, pp.29-38, 2011.
DOI : 10.1111/j.1541-0420.2010.01449.x

M. Simmonds, J. Higgins, L. Stewart, J. Tierney, M. Clarke et al., Meta-analysis of individual patient data from randomized trials: a review of methods used in practice, Clinical Trials, vol.2, issue.3, pp.209-226, 2005.
DOI : 10.1191/1740774505cn087oa

S. Spiro, L. James, and R. Rudd, Early Compared With Late Radiotherapy in Combined Modality Treatment for Limited Disease Small-Cell Lung Cancer: A London Lung Cancer Group Multicenter Randomized Clinical Trial and Meta-Analysis, Journal of Clinical Oncology, vol.24, issue.24, pp.3823-3853, 2006.
DOI : 10.1200/JCO.2005.05.3181

L. Stewart and M. Clarke, Practical methodology of meta-analyses (overviews) using updated individual patient data, Statistics in Medicine, vol.343, issue.19, pp.2057-79, 1995.
DOI : 10.1002/sim.4780141902

L. Stewart and M. Parmar, Meta-analysis of the literature or of individual patient data: is there a difference?, The Lancet, vol.341, issue.8842, pp.25-28, 1993.
DOI : 10.1016/0140-6736(93)93004-K

L. Stewart and J. Tierney, To IPD or not to IPD?, Evaluation & the Health Professions, vol.315, issue.1, pp.76-97, 2002.
DOI : 10.1177/0163278702025001006

G. Stewart, D. Altman, L. Askie, L. Duley, M. Simmonds et al., Statistical Analysis of Individual Participant Data Meta-Analyses: A Comparison of Methods and Recommendations for Practice, PLoS ONE, vol.7, issue.10, p.46042, 2012.
DOI : 10.1371/journal.pone.0046042.s003

L. Stewart, M. Clarke, M. Rovers, R. Riley, M. Simmonds et al., Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data, JAMA, vol.313, issue.16, pp.313-1657, 2015.
DOI : 10.1001/jama.2015.3656

J. Sun, Y. Ahn, and E. Choi, Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer, Annals of Oncology, vol.24, issue.8, pp.2088-92, 2013.
DOI : 10.1093/annonc/mdt140

L. Tian, L. Zhao, and L. Wei, Predicting the restricted mean event time with the subject's baseline covariates in survival analysis, Biostatistics, vol.15, issue.2, pp.222-233, 2014.
DOI : 10.1093/biostatistics/kxt050

L. Trinquart, J. Jacot, S. Conner, and R. Porcher, Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials, Journal of Clinical Oncology, vol.34, issue.15, pp.1813-1819, 2016.
DOI : 10.1200/JCO.2015.64.2488

T. Smith, C. Williamson, P. Marson, and A. , Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes, Statistics in Medicine, vol.90, issue.9, pp.1307-1326, 2005.
DOI : 10.1002/sim.2050

T. Smith, C. Williamson, and P. , A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes, Clinical Trials, vol.21, issue.6, pp.621-651, 2007.
DOI : 10.1177/1740774507085276

H. Uno, B. Claggett, and L. Tian, Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis, Journal of Clinical Oncology, vol.32, issue.22, pp.2380-2385, 2014.
DOI : 10.1200/JCO.2014.55.2208

H. Uno, J. Wittes, and H. Fu, Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies, Annals of Internal Medicine, vol.163, issue.2, pp.127-134, 2015.
DOI : 10.7326/M14-1741

Y. Wei, P. Royston, J. Tierney, and M. Parmar, Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data, Statistics in Medicine, vol.9, issue.4, pp.2881-98, 2015.
DOI : 10.1002/sim.6556

A. Whitehead, Meta-Analysis Of Controlled Clinical Trials, 2002.
DOI : 10.1002/0470854200

S. Yusuf, R. Peto, J. Lewis, R. Collins, and P. Sleight, Beta blockade during and after myocardial infarction: An overview of the randomized trials, Progress in Cardiovascular Diseases, vol.27, issue.5, pp.335-71, 1985.
DOI : 10.1016/S0033-0620(85)80003-7

X. Zhang, F. Loberiza, J. Klein, and M. Zhang, A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model, Computer Methods and Programs in Biomedicine, vol.88, issue.2, pp.95-101, 2007.
DOI : 10.1016/j.cmpb.2007.07.010

X. Zhang, Comparison of restricted mean survival times between treatments based on a stratified Cox model. Bio-Algorithms and Med-Systems, pp.183-189, 2013.

H. Zhao and A. Tsiatis, A consistent estimator for the distribution of quality adjusted survival time, Biometrika, vol.84, issue.2, pp.339-348, 1997.
DOI : 10.1093/biomet/84.2.339

H. Zhao and A. Tsiatis, Efficient Estimation of the Distribution of Quality-Adjusted Survival Time, Biometrics, vol.84, issue.4, pp.1101-1107, 1999.
DOI : 10.1111/j.0006-341X.1999.01101.x

L. Zhao, L. Tian, H. Uno, S. Solomon, M. Pfeffer et al., Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study, Clinical Trials, vol.82, issue.2, pp.570-577, 2012.
DOI : 10.1080/01621459.1989.10478874

L. Zhao, B. Claggett, and L. Tian, On the restricted mean survival time curve in survival analysis, Biometrics, vol.9, issue.1, pp.215-221, 2016.
DOI : 10.1111/biom.12384

D. Zucker, Restricted Mean Life with Covariates: Modification and Extension of a Useful Survival Analysis Method, Journal of the American Statistical Association, vol.344, issue.442, pp.702-709, 2014.
DOI : 10.1080/01621459.1998.10473722

. Gy, Earlier or shorter " : P: 80 mg/m², wks113 E: 100x3 mg/m², wks1 Later or longer " : P: 80 mg/m², wks1,4,7,10 E: 100x3 mg/m², wks1,4,7,10 " Earlier or shorter Later or longer, pp.4-5

. Gy, x 3 mg:m², wks4,10,16 E: 100 x 3 mg/m², wks4,10,16 alternating with C: 1000 mg/m², wks1,7,13 A: 50 mg/m², wks1,7,13 V: 2 mg, wks1,7,13 " Earlier or shorter " : 6 cycles (1 before RT, 1 during RT, 4 after RT) Later or longer, pp.25-31

. Hecog93, Earlier or shorter " : Day 1 " Later or longer, pp.1993-99

. Gy, 16 E: 100 x 3 mg/m² Earlier or shorter " : 6 cycles (1 during RT, 5 after RT) Later or longer, pp.6-11

B. Bronchus, . Calgb, L. Cancer, and B. Group, Comprehensive Cancer Centre of Wake Forest University; ECOG = Eastern Cooperative Oncology Group; EORTC = European Organisation for Research and Treatment of Cancer; HeCOG = Hellenic Cooperative Oncology Group; JCOG = Japan Clinical Oncology Group; LLCG =London Lung Cancer Group; PCL = Petites Cellules Limitées DISCLOSURE Consultant or Advisory Role

P. Baas and M. Sharp-dohme, AstraZeneca/Verastem; Lesley Seymour, Innate Pharma Research Funding: Paul Baas, Merck Sharp Dohme/Bristol-Myers Squibb Merck Sharp Dohme All remaining authors have declared no conflicts of interest. REFERENCES 1 Small-cell lung cancer, Lancet, vol.378, pp.1741-55, 2011.

F. Shepherd, J. Crowley, and P. Van-houtte, The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer, Journal of Thoracic Oncology, vol.2, issue.12, pp.1067-77, 2007.
DOI : 10.1097/JTO.0b013e31815bdc0d

R. Arriagada, L. Chevalier, T. Pignon, J. Rivière, A. Monnet et al., Initial Chemotherapeutic Doses and Survival in Patients with Limited Small-Cell Lung Cancer, New England Journal of Medicine, vol.329, issue.25, pp.1848-52, 1993.
DOI : 10.1056/NEJM199312163292504

J. Pignon, R. Arriagada, and D. Ihde, A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer, New England Journal of Medicine, vol.327, issue.23, pp.1618-1642, 1992.
DOI : 10.1056/NEJM199212033272302

R. Stahel, N. Thatcher, and M. Fruh, 1st ESMO Consensus Conference in lung cancer; Lugano 2010: Small-cell lung cancer, Annals of Oncology, vol.22, issue.9, pp.1973-80, 2011.
DOI : 10.1093/annonc/mdr313

A. Aupérin, R. Arriagada, and J. Pignon, Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission, New England Journal of Medicine, vol.341, issue.7, pp.476-84, 1999.
DOI : 10.1056/NEJM199908123410703

L. Péchoux, C. Dunant, A. Senan, and S. , Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial, The Lancet Oncology, vol.10, issue.5, pp.467-74, 2009.
DOI : 10.1016/S1470-2045(09)70101-9

M. Pijls-johannesma, D. Ruysscher, D. Lambin, and P. , Early versus late chest radiotherapy in patients with limited-stage small cell lung cancer, Cochrane Database Syst Rev, vol.27, issue.1, pp.1-40, 2005.
DOI : 10.1002/14651858.CD004700.pub2

D. De-ruysscher, M. Pijls-johannesma, and J. Vansteenkiste, Systematic review and metaanalysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials, Ann Oncol Cancer Treat Rev, vol.17, issue.33, pp.543-52461, 2006.

M. Huncharek and R. Mcgarry, A Meta-Analysis of the Timing of Chest Irradiation in the Combined Modality Treatment of Limited-Stage Small Cell Lung Cancer, The Oncologist, vol.9, issue.6, pp.665-72, 2004.
DOI : 10.1634/theoncologist.9-6-665

A. Turrisi, K. Kim, and R. Blum, Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide, New England Journal of Medicine, vol.340, issue.4, pp.265-71, 1999.
DOI : 10.1056/NEJM199901283400403

M. Schemper and T. Smith, A note on quantifying follow-up in studies of failure time, Controlled Clinical Trials, vol.17, issue.4, pp.343-346, 1996.
DOI : 10.1016/0197-2456(96)00075-X

J. Higgins and S. Thompson, Quantifying heterogeneity in a meta-analysis, Statistics in Medicine, vol.14, issue.11, pp.1539-58, 2002.
DOI : 10.1002/sim.1186

R. Dersimonian and N. Laird, Meta-analysis in clinical trials, Controlled Clinical Trials, vol.7, issue.3, pp.177-88, 1986.
DOI : 10.1016/0197-2456(86)90046-2

C. Early-breast, . Trialists-'collaborative, and . Group, Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women, Lancet, vol.339, pp.1-15, 1992.

B. Lueza, A. Mauguen, J. Pignon, O. Rivero-arias, and J. Bonastre, Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study, PLOS ONE, vol.14, issue.3, pp.150032-150042, 2016.
DOI : 10.1371/journal.pone.0150032.s006
URL : https://hal.archives-ouvertes.fr/inserm-01441469

B. Lueza, F. Rotolo, J. Bonastre, J. Pignon, and S. Michiels, Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis, BMC Medical Research Methodology, vol.15, issue.1, pp.37-47, 2016.
DOI : 10.1371/journal.pone.0150032
URL : https://hal.archives-ouvertes.fr/inserm-01441487

M. Perry, J. Herndon, and W. Eaton, Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083., Journal of Clinical Oncology, vol.16, issue.7, pp.2466-67, 1998.
DOI : 10.1200/JCO.1998.16.7.2466

N. Murray, P. Coy, and J. Pater, Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group., Journal of Clinical Oncology, vol.11, issue.2, pp.336-380, 1993.
DOI : 10.1200/JCO.1993.11.2.336

A. Gregor, P. Drings, and J. Burghouts, Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study., Journal of Clinical Oncology, vol.15, issue.8, pp.2840-2849, 1997.
DOI : 10.1200/JCO.1997.15.8.2840

M. Takada, M. Fukuoka, and M. Kawahara, Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104, Journal of Clinical Oncology, vol.20, issue.14, pp.3054-60, 2002.
DOI : 10.1200/JCO.2002.12.071

D. Skarlos, E. Samantas, and E. Briassoulis, Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG), Annals of Oncology, vol.12, issue.9, pp.1231-1239, 2001.
DOI : 10.1023/A:1012295131640

A. Blackstock, J. Bogart, C. Matthews, and C. , Split-Course Versus Continuous Thoracic Radiation Therapy for Limited-Stage Small-Cell Lung Cancer: Final Report of a Randomized Phase III Trial, Clinical Lung Cancer, vol.6, issue.5, pp.287-92, 2005.
DOI : 10.3816/CLC.2005.n.007

B. Lebeau, T. Urban, and J. Brechot, A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma, Cancer, vol.15, issue.8, pp.1480-1487, 1999.
DOI : 10.1002/(SICI)1097-0142(19991015)86:8<1480::AID-CNCR14>3.0.CO;2-O

E. Work, O. Nielsen, and S. Bentzen, Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group., Journal of Clinical Oncology, vol.15, issue.9, pp.3030-3037, 1997.
DOI : 10.1200/JCO.1997.15.9.3030

S. Park, G. Kim, and S. Jeong, The effects according to the timing of thoracic radiotherapyin limited stage small cell lung cancer, Tuberculosis and Respiratory Diseases, vol.43, issue.6, pp.903-918, 1996.
DOI : 10.4046/trd.1996.43.6.903

B. Jeremic, Y. Shibamoto, and L. Acimovic, Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study., Journal of Clinical Oncology, vol.15, issue.3, pp.893-900, 1997.
DOI : 10.1200/JCO.1997.15.3.893

L. Stewart and M. Parmar, Meta-analysis of the literature or of individual patient data: is there a difference?, The Lancet, vol.341, issue.8842, pp.25-33, 1993.
DOI : 10.1016/0140-6736(93)93004-K

A. Pelayo, R. Gallego, C. Bonfill, and V. Agra, Chemotherapy versus best supportive care for extensive small cell lung cancer, Cochrane Database Syst Rev, vol.4, pp.1-44, 2009.

K. Kubota, T. Hida, and S. Ishikura, Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study, The Lancet Oncology, vol.15, issue.1, pp.106-119, 2014.
DOI : 10.1016/S1470-2045(13)70511-4

. Web-appendix, The search in PubMed MEDLINE was conducted on January 11 th 2007 and yielded 905 results (+138 references from other sources) The search conducted on February 21 st 2014, yielded 1,285 results in Pubmed. Only one new trial (Sun et al. 2013) was considered appropriate to be included in the meta-analysis and therefore a sensitivity analysis including this trial was performed. The initial search is described below. Electronic Databases A modified search strategy for retrieving randomised controlled trials (RCTs) from Medline, developed by the Cochrane Collaboration A1 was used, Search strategy An initial search was done in 2007, and then updated addition, the following electronic bibliographic databases were searched: The Cochrane Central Register of Controlled Trials (CENTRAL) and the Proceedings of ASCO 1995, 2007.

M. And, Lung Neoplasms/radiotherapyRandomized Controlled Trials"[MeSH Terms]) OR ("Lung Neoplasms/radiotherapy"[MAJR] AND random*

C. Lefebvre and M. Clarke, Identifying Randomised Trials Systematic Reviews in Healthcare, pp.69-87, 2002.

A. Stewart, L. Clarke, and M. On, Practical methodology of meta-analyses (overviews) using updated individual patient data, Statistics in Medicine, vol.343, issue.19, pp.2057-79, 1995.
DOI : 10.1002/sim.4780141902

$. Medians, Range] are given for observed values * Trials are chronologically ordered within each category of trials (Similar CT compliance and Different CT compliance)

J. Japan, Clinical Oncology Group; LLCG = London Lung Cancer Group